Prophylactic and therapeutic treatment of alzheimer's disease using phytic acid and phytate to reduce amyloid beta plaque and tau protein

Abstract

A composition and method for the treatment of Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, amyloidosis and amyotrophic lateral sclerosis, includes an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered to a person in an amount from about 0.5 grams to about 18.75 grams per day.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . A method for the treatment of Alzheimer's disease and related amyloid plaque development, attenuating amyloid toxicity or plaque formation and reduction of amyloid plaque, protein aggregation and amyloidosis consisting essentially of the steps of orally administering to a patient afflicted with Alzheimer's disease an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered in an amount from about 0.5 grams to about 18.75 grams per day to effectively attenuate APP CTF-induced neurotoxicity to treat Alzheimer's disease and related amyloid plaque development and reduce amyloid plaque, amyloid plaque protein aggregation and amyloidosis. 
     
     
         4 . The method for the treatment of Alzheimer's disease and related amyloid plaque development, attenuating amyloid toxicity or plaque formation and reduction of amyloid plaque, protein aggregation and amyloidosis as in  claim 3  wherein the steps of administering an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, is administered in an amount from about 5 grams to about 9 grams per day in a single dose. 
     
     
         5 . The method for the treatment of Alzheimer's disease and related amyloid plaque development, attenuating amyloid toxicity or plaque formation and reduction of amyloid plaque, protein aggregation and amyloidosis as in  claim 3  wherein the steps of administering an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, is administered in an amount from about 2 grams to about 18.75 grams per day. 
     
     
         6 . A method for the treatment of Alzheimer's disease and related amyloid plaque development, attenuating amyloid toxicity or plaque formation and reduction of amyloid plaque, protein aggregation and amyloidosis comprising the steps of orally administering to a patient afflicted with Alzheimer's disease an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, being administered in an amount from about 0.5 grams to about 18.75 grams per day to effectively attenuate APP CTF-induced neurotoxicity to treat Alzheimer's disease and related amyloid plaque development and reduce amyloid plaque, protein aggregation and amyloidosis, wherein said step of administering an effective amount of said compound is the only step performed for treating Alzheimer's disease and related amyloid plaque development and reduction of amyloid plaque, protein aggregation and amyloidosis. 
     
     
         7 . The method for the treatment of Alzheimer's disease and related amyloid plaque development attenuating amyloid toxicity or plaque formation and reduction of amyloid plaque, protein aggregation and amyloidosis as in  claim 6  wherein the steps of administering an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, is administered in an amount from about 5 grams to about 9 grams per day in a single dose. 
     
     
         8 . The method for the treatment of Alzheimer's disease and related amyloid plaque development attenuating amyloid toxicity or plaque formation, and reduction of amyloid plaque, protein aggregation and amyloidosis as in  claim 6  wherein the steps of administering an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, is administered in an amount from about 2 grams to about 18.75 grams per day. 
     
     
         9 . The method of  claim 3 , wherein said compound is administered to a patient on an empty stomach. 
     
     
         10 . A method for the treatment of protein aggregating diseases consisting essentially of the steps of orally administering to a patient afflicted with one or more protein aggregating diseases an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof being administered in an amount from about 0.5 grams to about 18.75 grams per day to effectively treat protein aggregating diseases. 
     
     
         11 . A method for the prevention of aggregation of beta amyloid proteins consisting essentially of the steps of orally administering to a patient an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate or phytic acid or a phytate salt, or a mixture of any combination thereof being administered in an amount from about 0.5 grams to about 18.75 grams per day to effectively prevent Alzheimer's Disease. 
     
     
         12 . The method of  claim 11  wherein the steps of administering an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, is administered in an amount from about 5 grams to about 9 grams per day in a single dose. 
     
     
         13 . The method of  claim 11  wherein the steps of administering an effective amount of a compound selected from the group consisting of phytic acid, a phytate salt, an isomer or hydrolysate of phytic acid or a phytate salt, or a mixture of any combination thereof, is administered in an amount from about 2 grams to about 18.75 grams per day. 
     
     
         14 . The method of  claim 11  wherein said step of administering an effective amount of said compound is the only step performed for preventing Alzheimer's disease. 
     
     
         15 . The method of  claim 11 , wherein said compound is administered to a patient on an empty stomach. 
     
     
         16 . The method of  claim 11 , wherein said compound is the only active substance administered. 
     
     
         17 . The method of  claim 3 , wherein said compound is administered in liquid form. 
     
     
         18 . The method of  claim 11 , wherein said compound is infused into water. 
     
     
         19 . The method of  claim 11 , wherein said final concentration of said compound in water is 2%.